LunchTime Series Webinar April 29, 2014 at 12:00pm PST
ASCO is deeply concerned about the recent release of Medicare physician payment data. The data release solely focuses attention on the dollars paid to practices for the medical care and treatment of patients on Medicare, rather than contributing to the ongoing national conversation about value and quality in health care. The data released by Medicare was issued with no context or explanation about the complexity of the payment system, the value of the services provide, and the needs of patients with cancer. Compounding this situation were the extensive inaccuracies in the data for many oncologists. Of specific concern is that most of the amounts shown in the Medicare database for oncologist are not, in fact, revenue to oncology practices. Instead, these Medicare payments merely cover the upfront costs of purchasing drugs for patients. The data release is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Physician-and-Other-Supplier.html. Immediately following CMS' release of Medicare payment data last week, lawyers who specialize in representing health care fraud whistleblowers began mining the information for possible indications of fraud, Reuters reports. Such lawyers focus on bringing cases against drug makers and providers on behalf of employees who think other workers might be committing Medicare fraud. For more information, click here.
CMS has created the new Multiple Locations Tipsheet for eligible professionals practicingmultiple locations. The Tipsheet provides information on how to successfully demonstrate meaningful use in the Medicare and Medicaid EHR Incentive Programs. The Tipsheet includes guidance on determining if a location is equipped with certified EHR technology, calculating patient encounters, and what to do when different menu objectives and clinical quality measures (CQMs) are chosen across locations. Visit the CMS EHR Incentive Programs website for more resources to help you successfully participate. For more information, click here.
ANCO and MOASC urge all members to contact their State Senators and urge them to oppose SB1215 that would eliminate the in-office exception to the self-referral prohibition for advanced imaging, radiation therapy, anatomic pathology, and physical therapy. In effect, passage of SB1215 would outlaw integrated cancer care in a single practice in California and outlaw multidisciplinary oncology practice in California. For more information, click here.
The following updates have been posted to the Noridian/JEMAC website (http://med.noridianmedicare.com/web/jeb): Electronic Funds Transfer: What Providers Need to Know; Noridian Assigned ICD-9-CM Codes for NCDs Article Retirement; Clinical Laboratory Fee Schedule and Laboratory Services Subject to Reasonable Charge Payment Annual Update--Revision; For more information, click here.
The deadline for providers to apply for Medi-Cal EHR incentive payments for the 2013 program year has been extended by one month to April 30. After that date, the State Level Registry (SLR) will no longer accept 2013 applications. For more information, visit the SLR website www.medi-cal.ca.gov. For more information, click here.
LunchTime Series held on March 26, 2014. Topic was: Surviving Covered California - What Physician Practices Need to Know Presented by:Mitzi Young, CMA Center for Economic Services What Attendees Can Expect to Learn:
For more information on this webinar, click here or contact the MOASC Office at firstname.lastname@example.org or 909.985.9061, ext. 1.
MOASC would like to introduce two of our newest sponsor’s:
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad offers an array of genetic tests, prognostic tests and personalized medicine tests to help healthcare providers assess a patient's increased cancer risk, disease aggressiveness and optimize efficacy of chemotherapy. Myriad's testing products can provide healthcare providers with information to help make medical management decisions to reduce cancer risk and help make sure specific treatments are tailored for each individual patient. For more information, visit https://www.myriad.com/
Rosetta Genomics, Ltd. is a leading molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its proprietary microRNAs and platform technologies. Backed by a strong IP portfolio, Rosetta Genomics’ scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, cardiovascular diseases and other indications. The Company’s four commercial oncology tests have been launched in multiple countries worldwide via partners, and by a Company-led effort in the U.S. The Company is now working to develop additional tests in the cancer realm and in other fields.
Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta Genomics' testing services are commercially available through its Philadelphia-based CAP accredited, CLIA certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award. For more information, visit http://rosettagenomics.com/
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.